Precision BioSciences (FRA:PBS0) ROCE % : 28.10% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Precision BioSciences's annualized ROCE % for the quarter that ended in Mar. 2024 was 28.10%.

Precision BioSciences ROCE % Historical Data

The historical data trend for Precision BioSciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences ROCE % Chart

Precision BioSciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-56.19

-65.00

-22.14

-41.86

-27.45

Precision BioSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-31.78	-31.85	-38.91	-45.50	28.10

Precision BioSciences ROCE % Calculation

Precision BioSciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-36.952	/	( ( (224.832 - 56.323)	+	(146.519 - 45.838) )	/ 2 )
	=	-36.952	/	( (168.509	+	100.681)	/ 2 )
	=	-36.952	/	134.595
	=	-27.45 %

Precision BioSciences's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	33.716	/	( ( (146.519 - 45.838)	+	(169.962 - 30.671) )	/ 2 )
	=	33.716	/	( ( 100.681	+	139.291 )	/ 2 )
	=	33.716	/	119.986
	=	28.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Precision BioSciences (FRA:PBS0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Precision BioSciences ROCE % Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Precision BioSciences (FRA:PBS0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (FRA:PBS0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DTIL:USA

Address

302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701

Website

https://www.precisionbiosciences.com

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Precision BioSciences (FRA:PBS0) Headlines

No Headlines